Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (Review)

Zeng,Hai; Zhang,Fan; Sun,Yujiao; Li,Shuang; Zhang,Weijia

doi:10.3892/mco.2023.2702

Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (Review)

Authors:
- Hai Zeng
- Fan Zhang
- Yujiao Sun
- Shuang Li
- Weijia Zhang
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China, Department of Clinical Medicine, Medical School of Yangtze University, Jingzhou, Hubei 434000, P.R. China
Published online on: November 20, 2023 https://doi.org/10.3892/mco.2023.2702
Article Number: 4
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Compared with postoperative adjuvant therapy, neoadjuvant therapy has more potential advantages, such as decreasing tumor stage, killing micrometastatic cells. Because of these advantages, neoadjuvant therapy is recommended for numerous types of tumor, such as breast, lung and rectal cancer. To determine the role of neoadjuvant therapy on overall survival and adverse for patients with resectable esophageal carcinoma. we summarized clinical studies on 7 types of neoadjuvant therapies in this review. Currently, patients with esophageal cancer (EC) in China mainly receive postoperative treatment with <30% of patients receiving neoadjuvant therapy. One reason for the limited use of neoadjuvant therapy in China is inaccurate staging based on imaging and neoadjuvant treatment may increase difficulties in surgery. After neoadjuvant therapy, there may be tissue edema, blurry surgical field of view and unclear tissue gaps, resulting in greater difficulty in surgical procedures. However, oncologists are interested in neoadjuvant treatment, especially neoadjuvant immunotherapy to treat EC. Concurrent chemoradiotherapy for esophageal squamous cell carcinoma (ESCC) is the most common neoadjuvant treatment regimen and increases the pathological complete response (pCR) and 5‑ and 10‑year survival rates. Preoperative induction chemotherapy and sequential concurrent chemoradiotherapy are currently the most widely treatments used in clinical practice in China. However, this treatment strategy does not yield long‑term survival. The pCR rate of neoadjuvant immunotherapy is greater than that of concurrent chemoradiotherapy but, to the best of our knowledge, no evidence of long‑term survival benefit has been found in phase I and II clinical trials. Neoadjuvant treatment should be considered for patients with locally advanced ESCC.

View Figures

View References

1	World Health Organization (WHO): International agency for research on cancer. GLOBOCAN 2020: Oesophagus cancer fact sheet. WHO, Geneva, 2020.
2	Codipilly DC and Wang KK: Squamous cell carcinoma of the esophagus. Gastroenterol Clin North Am. 51:457–484. 2022.PubMed/NCBI View Article : Google Scholar
3	Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X and Chen W: Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237. 2016.PubMed/NCBI View Article : Google Scholar
4	Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J and Arnold M: The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology. 163:649–658.e2. 2022.PubMed/NCBI View Article : Google Scholar
5	Kauppila JH, Mattsson F, Brusselaers N and Lagergren J: Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open. 8(e021495)2018.PubMed/NCBI View Article : Google Scholar
6	Wang Z, Shao C, Wang Y, Duan H, Pan M, Zhao J, Wang J, Ma Z, Li X and Yan X: Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis. Int J Surg. 104(106767)2022.PubMed/NCBI View Article : Google Scholar
7	Deng J, Wang C, Xiang M, Liu F, Liu Y and Zhao K: Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagn Pathol. 9(151)2014.PubMed/NCBI View Article : Google Scholar
8	Wang Z, Sun S, Li K, Huang C, Liu X, Zhang G and Li X: Feasibility analysis of combined surgery for esophageal cancer. World J Surg Oncol. 21(41)2023.PubMed/NCBI View Article : Google Scholar
9	Launois B, Delarue D, Campion JP and Kerbaol M: Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet. 153:690–692. 1981.PubMed/NCBI
10	van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012.PubMed/NCBI View Article : Google Scholar
11	Zhao S, Qi W and Chen J: Role of a multidisciplinary team in administering radiotherapy for esophageal cancer. BMC Cancer. 20(974)2020.PubMed/NCBI View Article : Google Scholar
12	Chinese Society of Clinical Oncology (CSCO): Guidelines of Chinese society of clinical oncology (CSCO) Esophageal cancer. CSCO, 2023.
13	Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus. 16:25–43. 2019.PubMed/NCBI View Article : Google Scholar
14	Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, et al: Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 21:393–422. 2023.PubMed/NCBI View Article : Google Scholar
15	Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z, Wu Y, Feng X, Qi W, Chen K, et al: Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 144:232–241. 2021.PubMed/NCBI View Article : Google Scholar
16	Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP and Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 73:1779–1784. 1994.PubMed/NCBI View Article : Google Scholar
17	Almhanna K, Shridhar R and Meredith KL: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: Is there a standard of care? Cancer Control. 20:89–96. 2013.PubMed/NCBI View Article : Google Scholar
18	Schlag PM: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The chirurgische arbeitsgemeinschaft fuer onkologie der deutschen gesellschaft fuer chirurgie study group. Arch Surg. 127:1446–1450. 1992.PubMed/NCBI View Article : Google Scholar
19	Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 339:1979–1984. 1998.PubMed/NCBI View Article : Google Scholar
20	Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, et al: Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 25:3719–3725. 2007.PubMed/NCBI View Article : Google Scholar
21	Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M (eds): Esophagus. In: American Joint Committee on Cancer (AJCC) cancer staging manual. 6th edition. New York, NY: Springer, pp167-178, 2002.
22	Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067. 2009.PubMed/NCBI View Article : Google Scholar
23	Loc NVV, Vuong NL, Trung LV and Trung TT: Effect of time to minimally invasive esophagectomy after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. J Gastrointest Cancer. 1–12. 2023.PubMed/NCBI View Article : Google Scholar : (Epub ahead of print).
24	Depypere L: The effect of time interval on esophagectomy after neoadjuvant treatment. Ann Transl Med. 4(117)2016.PubMed/NCBI View Article : Google Scholar
25	Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A and Franceschi D: Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. J Surg Res. 216:65–72. 2017.PubMed/NCBI View Article : Google Scholar
26	Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, et al: Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 43:752–755. 2013.PubMed/NCBI View Article : Google Scholar
27	Matsuda S, Kitagawa Y, Takemura R, Okui J, Okamura A, Kawakubo H, Muto M, Kakeji Y, Takeuchi H, Watanabe M and Doki Y: Real-world evaluation of the efficacy of neoadjuvant DCF Over CF in esophageal squamous cell carcinoma: Propensity score-matched analysis from 85 authorized institutes for esophageal cancer in Japan. Ann Surg. 278:e35–e42. 2023.PubMed/NCBI View Article : Google Scholar
28	Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Iwahashi M and Yamaue H: Neoadjuvant chemotherapy with divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus. Anticancer Res. 36:829–834. 2016.PubMed/NCBI
29	Sobin LH, Gospodarowicz MK and Wittekind C (eds): TNM classification of malignant tumors. 7th edition. Oxford: Wiley-Blackwell, 2010.
30	Hayata K, Ojima T, Nakamori M, Nakamura M, Katsuda M, Kitadani J, Takeuchi A, Tabata H, Maruoka S and Yamaue H: Neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable advanced esophageal cancer. Anticancer Res. 38:5267–5273. 2018.PubMed/NCBI View Article : Google Scholar
31	Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet. 359:1727–1733. 2002.PubMed/NCBI View Article : Google Scholar
32	Chan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, Zhu X and Wong RKS: Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. Int J Cancer. 143:430–437. 2018.PubMed/NCBI View Article : Google Scholar
33	Abouarab MH, Salem IL, Degheidy MM, Henn D, Hirche C, Eweida A, Uhl M, Kneser U and Kremer T: Therapeutic options and postoperative wound complications after extremity soft tissue sarcoma resection and postoperative external beam radiotherapy. Int Wound J. 15:148–158. 2018.PubMed/NCBI View Article : Google Scholar
34	Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M and Kerin M: Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol. 25:4850–4869. 2019.PubMed/NCBI View Article : Google Scholar
35	Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, et al: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. Lancet Oncol. 22:29–42. 2021.PubMed/NCBI View Article : Google Scholar
36	Choi YS, Sin JI, Kim JH, Ye GW, Shin IH and Lee TS: Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J Korean Med Sci. 21:683–689. 2006.PubMed/NCBI View Article : Google Scholar
37	Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ and Zhang DW: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: Report on 206 patients. Int J Radiat Oncol Biol Phys. 16:325–327. 1989.PubMed/NCBI
38	Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E, Rosengren B, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16:1104–1110. 1992.PubMed/NCBI View Article : Google Scholar
39	Huang Y, Wang H, Luo G, Zhang Y, Wang L and Li K: A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. Int J Surg. 38:41–47. 2017.PubMed/NCBI View Article : Google Scholar
40	Lehrer E, Geyer S, Goodrich A, Ilson DH, Noonan A, Dumane VA and Goodman KA: Impact of lung and heart radiation dose during preoperative chemoradiation on overall survival (OS) in esophageal cancer (EC)-secondary analysis of CALGB 80803 (Alliance). Iscahn school of medicine at mount sinai. ASTRO. 114 (Suppl)(S13)2022.
41	Sobin LH and Fleming ID: TNM classification of malignant tumors. 5th edition. John Wiley and Sons, New York, NY, 1997.
42	Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, et al: Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: Final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 32:2416–2422. 2014.PubMed/NCBI View Article : Google Scholar
43	Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III Multicenter, Randomized, open-label clinical trial. J Clin Oncol. 36:2796–2803. 2018.PubMed/NCBI View Article : Google Scholar
44	Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, et al: Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 randomized clinical trial. JAMA Surg. 156:721–729. 2021.PubMed/NCBI View Article : Google Scholar
45	Guo X, Wang Z, Yang H, Mao T, Chen Y, Zhu C, Yu Z, Han Y, Mao W, Xiang J, et al: Impact of lymph node dissection on survival after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: From the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg. 277:259–266. 2023.PubMed/NCBI View Article : Google Scholar
46	Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, et al: A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 27:660–667. 2016.PubMed/NCBI View Article : Google Scholar
47	Li J: Neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: A stabilized inverse probability of treatment weighting analysis. ASTRO. 114 (Suppl):E162–E163. 2022.
48	Hamai Y, Hihara J, Taomoto J, Yamakita I, Ibuki Y and Okada M: Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Dis Esophagus. 28:358–364. 2015.PubMed/NCBI View Article : Google Scholar
49	Sathornviriyapong S, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Kawano Y, Yamada M and Uchida E: Impact of neoadjuvant chemoradiation on short-term outcomes for esophageal squamous cell carcinoma patients: A meta-analysis. Ann Surg Oncol. 23:3632–3640. 2016.PubMed/NCBI View Article : Google Scholar
50	Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, Bonavina L, Rosman C, van Berge Henegouwen MI, Gisbertz SS and van der Peet DL: Minimally invasive versus open esophageal resection: Three-year follow-up of the previously reported randomized controlled trial: The TIME trial. Ann Surg. 266:232–236. 2017.PubMed/NCBI View Article : Google Scholar
51	Rice TW, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BP, Chen KL, Davies AR, D'Journo XB, Kesler KA, et al: Worldwide Esophageal Cancer Collaboration: Pathologic staging data. Dis Esophagus. 29:724–733. 2016.PubMed/NCBI View Article : Google Scholar
52	Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, et al: Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: A randomized clinical trial. JAMA Surg. 156:444–451. 2021.PubMed/NCBI View Article : Google Scholar
53	Al-Kaabi A, van der Post RS, van der Werf LR, Wijnhoven BPL, Rosman C, Hulshof MCCM, van Laarhoven HWM, Verhoeven RHA and Siersema PD: Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: A population-based study. Acta Oncol. 60:497–504. 2021.PubMed/NCBI View Article : Google Scholar
54	Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, et al: Positron-emission tomography scan-directed chemoradiation for esophageal squamous cell carcinoma: No benefit for a change in chemotherapy in positron-emission tomography nonresponders. J Thorac Oncol. 14:540–546. 2019.PubMed/NCBI View Article : Google Scholar
55	Li CC, Chen CY, Chou YH, Huang CJ, Ku HY, Lin YC and Chien CR: High vs low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: An endemic area population-based study. Discov Oncol. 13(130)2022.PubMed/NCBI View Article : Google Scholar
56	Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, BalmerMajno S, et al: Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 20:1522–1528. 2009.PubMed/NCBI View Article : Google Scholar
57	Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, et al: A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 78:91–99. 2016.PubMed/NCBI View Article : Google Scholar
58	Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, et al: A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 24:2844–2849. 2013.PubMed/NCBI View Article : Google Scholar
59	Harada G, Bonadio RRDCC, de Araújo FCC, Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR and de Castria TB: Induction chemotherapy for locally advanced esophageal cancer. J Gastrointest Cancer. 51:498–505. 2020.PubMed/NCBI View Article : Google Scholar
60	Gao LR, Li C, Han W, Ni W, Deng W, Li Y and Xiao Z: Survival benefit of surgery in patients with clinical T4 esophageal cancer responded to neoadjuvant chemoradiotherapy/radiotherapy. ASTRO. 114 (Suppl)(E159)2022.PubMed/NCBI View Article : Google Scholar
61	Emens LA and Middleton G: The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res. 3:436–443. 2015.PubMed/NCBI View Article : Google Scholar
62	Yu WD, Sun G, Li J, Xu J and Wang X: Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 452:66–70. 2019.PubMed/NCBI View Article : Google Scholar
63	Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA and Tawbi HA: Development of immunotherapy combination strategies in cancer. Cancer Discov. 11:1368–1397. 2021.PubMed/NCBI View Article : Google Scholar
64	Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al: Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet. 398:759–771. 2021.PubMed/NCBI View Article : Google Scholar
65	Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al: Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 21:832–842. 2020.PubMed/NCBI View Article : Google Scholar
66	Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, et al: Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 10(e003497)2022.PubMed/NCBI View Article : Google Scholar
67	Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 151:128–137. 2022.PubMed/NCBI View Article : Google Scholar
68	Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 10(e004291)2022.PubMed/NCBI View Article : Google Scholar
69	Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G, Zhong R, You Z, Wang R, Lu Y, et al: Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: A systematic review and meta-analysis. JAMA Netw Open. 5(e2239778)2022.PubMed/NCBI View Article : Google Scholar
70	Liu Y, Bao Y, Men Y, Wang Y and Hui Z: Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy vs combined with chemotherapy in esophageal cancer: A systematic review and meta-analysis. ASTRO. 114 (Suppl):E163–E164. 2022.PubMed/NCBI View Article : Google Scholar
71	Hong HE, Kim HR, Park SY, Kim DJ, Lee CG, Cho J, Kim JH, Kim HR, Kim YH, Park SR and Cho BC: A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 37 (Suppl)(S4027)2019.
72	van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, et al: Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT). Clin Cancer Res. 27:3351–3359. 2021.PubMed/NCBI View Article : Google Scholar
73	Brenner B, Purim O, Gordon N, Goshen-Lago T, Idelevich E, Kashtan H, Menasherov N, Fenig E, Sulkes A and Kundel Y: The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. Radiother Oncol. 134:74–80. 2019.PubMed/NCBI View Article : Google Scholar
74	Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, et al: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol. 29:626–631. 2011.PubMed/NCBI View Article : Google Scholar
75	Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, et al: Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: A randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 29:1386–1393. 2018.PubMed/NCBI View Article : Google Scholar
76	Ye P: To explore the effect of the number of administration cycles of camrelizumab combined with chemotherapy on neoadjuvant therapy for stage IIB-IVA thoracic resectable esophageal cancer. Registration number: ChiCTR2200061139. Date of Registration: 2022-06-15.
77	Yi Z: Real-World clinical study of cindimizumab combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer. Registration number: ChiCTR2100050561. Date of Registration: 2021-08-28.